Autism Spectrum Disorder (ASD) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Autism Spectrum Disorder (ASD) – Drugs In Development, 2023’, provides an overview of the Autism Spectrum Disorder (ASD) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Autism Spectrum Disorder (ASD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Autism Spectrum Disorder (ASD) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Autism Spectrum Disorder (ASD)
- The report reviews pipeline therapeutics for Autism Spectrum Disorder (ASD) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Autism Spectrum Disorder (ASD) therapeutics and enlists all their major and minor projects
- The report assesses Autism Spectrum Disorder (ASD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Autism Spectrum Disorder (ASD)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Autism Spectrum Disorder (ASD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Autism Spectrum Disorder (ASD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Aardvark Therapeutics IncAbbVie Inc
Acadia Pharmaceuticals Inc
Aelis Farma SAS
AgeneBio Inc
AgoneX Biopharmaceuticals Inc
Allos Pharma Inc
Astrogen Ltd
Avekshan LLC
Axial Therapeutics Inc
Beijing Joekai Biotechnology Co Ltd
Beyond Air Inc
Bio-Modeling Systems SAS
Bioprojet SCR
BnH Research
Boehringer Ingelheim International GmbH
BrainStorm Cell Therapeutics Inc
CAMP Therapeutics Inc
Canopy Growth Corp
Cennerv Pharma (S) Pte Ltd
ChunLab Inc
Compass Pathways Plc
Connecta Therapeutics SL
Coronis NeuroSciences Ltd
Cox Biosciences LLC
Curemark LLC
Elphis Cell Therapeutics Co Ltd
Endeavour Cells ApS
Enterin Inc
Epigen Biosciences Inc
EuMentis Therapeutics Inc
F. Hoffmann-La Roche Ltd
FamiCord Group
Gedeon Richter Plc
HealthBiome Inc
Hopstem Biotechnology LLC
IAMA Therapeutics Srl
iCELL Biotechnology Co Ltd
ImmunoBiome Inc
Immuron Ltd
Interon Laboratories Inc
Intra-Cellular Therapies Inc
Intrinsic Medicine Inc
Italian Institute of Technology
Jaguar Gene Therapy LLC
Jazz Pharmaceuticals Plc
JC Pharma Inc
Johnson & Johnson
KoBioLabs Inc
Kuzani Pharmaceuticals Inc
Lab1636
London Research & Pharmaceuticals Ltd
Malachite Innovations Inc
MapLight therapeutics Inc
Marvel Biotechnology Inc
MD Healthcare Inc
Merck & Co Inc
Mind Medicine MindMed Inc
Monument Therapeutics Ltd
Neurokine Therapeutics
Neurotech International Ltd
Neuroventi Co Ltd
Neurxstem Inc
NLS Pharmaceutics AG
Nova Mentis BioTech Corp
Omeros Corp
OptiNose Inc
Oryzon Genomics SA
Otsuka Pharmaceutical Co Ltd
Palisades Therapeutics
Panorama Research Institute
Parkure Ltd
Pastorus Pharma LLC
Paxmedica Inc
Psyneurgy Pharmaceuticals LLC
Q BioMed Inc
QurCan Therapeutics Inc
Rena Science Co Ltd
RespireRx Pharmaceuticals Inc
Rugen Therapeutics R&D (Shanghai) Co Ltd
Samara Regional Medical Center Dynasty
Scioto Biosciences Inc
SciSparc Ltd
Sengenics Corp Pte Ltd
Shenzhen Wanhe Pharmaceutical Co Ltd
SkySea Pharmaceutical Inc
Stalicla SA
Standigm Inc
Stem Cell Medicine Ltd
Sumitomo Pharma Co Ltd
Synaptogenix Inc
Taysha Gene Therapies Inc
The Greater Cannabis Company Inc
The University of Tokyo Hospital
Tonix Pharmaceuticals Holding Corp
University of Minnesota
University of Texas Health Science Center at Houston
Vanda Pharmaceuticals Inc
Vanderbilt University
Vitro Biopharma Inc
Vitti Labs LLC
Yamo Pharmaceuticals LLC
Zelira Therapeutics Ltd
Zynerba Pharmaceuticals Inc